Interleukin-6: A critical cytokine in cancer multidrug resistance

Current Pharmaceutical Design

Volumn 22, Issue 5, 2016, Pages 518-526

  Ghandadi, Morteza ^a   Sahebkar, Amirhossein ^a,b  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Cancer; Chemotherapy; Cytokine; IL 6; Multidrug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 6;

CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INDUCTION; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; INFLAMMATION; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERLEUKIN-6; NEOPLASMS;

EID: 84958292261     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151124234417     Document Type: Review

References (83)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-44.
3. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-7.
4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
5. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
6. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007; 356: 2131-42.
7. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol 2004; 31: 12-21.
8. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-13.
9. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004; 14: 433-9.
10. Steiner PE, Loosli CG. The effect of human influenza virus (type A) on the incidence of lung tumors in mice. Cancer Res 1950; 10: 385-92.
11. Kolstad P, Klem V. Long-term followup of 1121 cases of carcinoma in situ. Obstet Gynecol 1976; 48: 125-9.
12. Miki C, Inoue Y, Araki T, Uchida K, Kusunoki M. Cytokines and cancer development. J Surg Oncol 2007; 95: 10-11.
13. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-35.
14. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22: 347-52.
15. Azuma MM, Samuel RO, Gomes-Filho JE, Dezan-Junior E, Cintra LT. The role of IL-6 on apical periodontitis: a systematic review. Int Endod J 2014; 47: 615-21.
16. Patel SA, Bhambra U, Charalambous MP, et al. Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3. Br J Cancer 2014; 111: 2287-96.
17. Duffy M. The war on cancer: are we winning? Tumor Biol 2013: 10.
18. Choi C-H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 2005; 5: 30.
19. Gimenez-Bonafe P, Tortosa A, Perez-Tomas R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 2009; 9: 320-40.
20. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP–dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
21. Gjertsen BT, Logothetis CJ, McDonnell TJ. Molecular regulation of cell death and therapeutic strategies for cell death induction in prostate carcinoma. Cancer Metastasis Rev 1998; 17: 345-51.
22. Burt R, Poirier M, Link C, Bohr V. Antineoplastic drug resistance and DNA repair. Annl Oncol 1991; 2: 325-34.
23. Juranka P, Zastawny R, Ling V. P-glycoprotein: multidrugresistance and a superfamily of membrane-associated transport proteins. FASEB J 1989; 3: 2583-92.
24. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665-70.
25. Váradi A, Szakács G, Bakos É, Sarkadi B. P glycoprotein and the mechanism of multidrug resistance. Novartis Found Symp 2002; 243: 54-65.
26. Deeley RG, Cole SP. Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol 1997; 8(3): 193-204.
27. Gibson CJ, Hossain MM, Richardson JR, Aleksunes LM. Inflammatory regulation of ATP binding cassette efflux transporter expression and function in microglia. J Pharmacol Exp Ther 2012; 343: 650-60.
28. Ho EA, Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr Cancer Drug Targets 2006; 6: 295-311.
29. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4: 221-33.
30. Perwez Hussain S, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007; 121: 2373-80.
31. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6: a016295.
32. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14: 109-19.
33. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22: 347-52.
34. Burger R. Impact of interleukin-6 in hematological malignancies. Transfus Med Hemother 2013; 40: 336-43.
35. Borsellino N, Belldegrun A, Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 1995; 55: 4633-9.
36. Domingo-Domenech J, Oliva C, Rovira A, et al. Interleukin 6, a nuclear factor-_B target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-_B inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 2006; 12: 5578-86.
37. Wu CT, Chen MF, Chen WC, Hsieh CC. The role of IL-6 in the radiation response of prostate cancer. Radiat Oncol 2013; 8: 159.
38. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994; 73: 1882-8.
39. Scambia G, Testa U, Panici PB, et al. Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer 1994; 57: 318-23.
40. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 1997; 66: 27-30.
41. Scambia G, Testa U, Panici PB, et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 1995; 71: 354.
42. Penson RT, Kronish K, Duan Z, et al. Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 2000; 10: 33-41.
43. Suh YA, Jo SY, Lee HY, Lee C. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells. Int J Oncol 2015; 46: 1405-11.
44. Wei LH, Kuo ML, Chen CA, et al. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene 2001; 20: 5799.
45. Bellone S, Watts K, Cane S, et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol 2005; 98: 92-8.
46. Zhang GJ, Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 1999; 19: 1427-32.
47. Shi Z, Yang WM, Chen LP, et al. Enhanced chemosensitization in multidrug-resistant human breast cancer cells by inhibition of IL-6 and IL-8 production. Breast Cancer Res Treatment 2012; 135: 737-47.
48. Conze D, Weiss L, Regen PS, et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001; 61: 8851-8.
49. Mosaffa F, Kalalinia F, Lage H, Afshari JT, Behravan J. Proinflammatory cytokines interleukin-1 beta, interleukin 6, and tumor necrosis factor-alpha alter the expression and function of ABCG2 in cervix and gastric cancer cells. Mol Cell Biochem 2012; 363: 385-93.
50. Liu Y, Li P-K, Li C, Lin J. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem 2010; 285: 27429-39.
51. Duan Z, Lamendola DE, Penson RT, Kronish KM, Seiden MV. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells. Cytokine 2002; 17: 234-42.
52. Chen CC, Chen WC, Lu CH, et al. Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys 2010; 76: 1214-24.
53. Stanam A, Love-Homan L, Joseph TS, Espinosa-Cotton M, Simons AL. Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma. Mol Oncol 2015.
54. Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee K-D. IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer 2013; 12: 26.
55. Pu YS, Hour TC, Chuang SE, Cheng AL, Lai MK, Kuo ML. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells. Prostate 2004; 60: 120-9.
56. Wang Y, Niu XL, Qu Y, et al. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett 2010; 295: 110-23.
57. Wang Y, Niu XL, Guo XQ, et al. IL6 induces TAM resistance via kinase-specific phosphorylation of ERalpha in OVCA cells. J Mol Endocrinol 2015; 54: 351-61.
58. Duan Z, Ames RY, Ryan M, Hornicek FJ, Mankin H, Seiden MV. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer Chemotherapy Pharmacol 2009; 63: 681-9.
59. Rebbaa A, Chou PM, Mirkin BL. Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis. Mol Med 2001; 7: 393.
60. Ara T, Nakata R, Sheard MA, et al. Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. Cancer Res 2013; 73(13): 3852-64.
61. Chen MF, Hsieh CC, Chen WC, Lai CH. Role of interleukin-6 in the radiation response of liver tumors. Int J Radiation Oncol Biol Phys 2012; 84(5): e621-30.
62. Lee G, Piquette-Miller M. Cytokines alter the expression and activity of the multidrug resistance transporters in human hepatoma cell lines; analysis using RT-PCR and cDNA microarrays. J Pharm Sci 2003; 92: 2152-63.
63. Lee G, Piquette-Miller M. Influence of IL-6 on MDR and MRPmediated multidrug resistance in human hepatoma cells. Can J Physiol Pharmacol 2001; 79: 876-84.
64. Hartmann G, Kim H, Piquette-Miller M. Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int Immunopharmacol 2001; 1: 189-99.
65. Sukhai M, Yong A, Pak A, Piquette-Miller M. Decreased expression of P-glycoprotein in interleukin-1_ and interleukin-6 treated rat hepatocytes. Inflam Res 2001; 50: 362-70.
66. Sukhai M, Yong A, Kalitsky J, Piquette-Miller M. Inflammation and interleukin-6 mediate reductions in the hepatic expression and transcription of the mdr1a and mdr1b genes. Mol Cell Biol Res Commun 2000; 4: 248-56.
67. Sukhai M, Pak A, Yong A, Piquette-Miller M. IL-6 decreases PGP expression in cultured rat hepatocytes. AAPS Pharm Sci 1999; 1: 249.
68. Diao L, Li N, Brayman TG, Hotz KJ, Lai Y. Regulation of MRP2/ABCC2 and BSEP/ABCB11 expression in sandwich cultured human and rat hepatocytes exposed to inflammatory cytokines TNF-_, IL-6, and IL-1_. J Biol Chem 2010; 285: 31185-92.
69. Fardel O, Le Vée M. Regulation of human hepatic drug transporter expression by pro-inflammatory cytokines. Expert Opin Drug Metabol Toxicol 2009; 5: 1469-81.
70. Le Vee M, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-_ or interleukin-6. Drug Metabol Disposit 2009; 37: 685-93.
71. Voorhees PM, Chen Q, Small GW, et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 2009; 145: 481-90.
72. Ohbayashi M, Yasuda M, Kawakami I, Kohyama N, Kobayashi Y, Yamamoto T. Effect of interleukins response to ECM-induced acquisition of drug resistance in MCF-7 cells. Exp Oncol 2008; 30: 276-82.
73. Ciocca DR, Fuqua SA, Lock-Lim S, Toft DO, Welch WJ, McGuire WL. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 1992; 52: 3648-54.
74. Haverty AA, Harmey JH, Redmond HP, Bouchier-Hayes DJ. Interleukin-6 upregulates GP96 expression in breast cancer. J Surg Res 1997; 69: 145-9.
75. Wang HW, Lin CP, Chiu JH, et al. Reversal of inflammationassociated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin. Int J Cancer 2007; 120: 2019-27.
76. Yan HQ, Huang XB, Ke SZ, et al. Interleukin 6 augments lung cancer chemotherapeutic resistance via ataxia-telangiectasia mutated/NF-kappaB pathway activation. Cancer Sci 2014; 105: 1220-7.
77. Tawara K, Oxford JT, Jorcyk CL. Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 2011; 3: 177-89.
78. Zhao Z, Cheng X, Wang Y, et al. Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis. PLoS One 2014; 9: e95884.
79. Waldner MJ, Foersch S, Neurath MF. Interleukin-6--a key regulator of colorectal cancer development. Int J Biol Sci 2012; 8: 1248-53.
80. Ho LJ, Luo SF, Lai JH. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers. Biochem Pharmacol 2015; 97: 16-26.
81. Rossi JF, Lu ZY, Jourdan M, Klein B. Interleukin-6 as a therapeutic target. Clin Cancer Res 2015; 21: 1248-57.
82. Alberti L, Thomachot MC, Bachelot T, Menetrier-Caux C, Puisieux I, Blay JY. IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer 2004; 111: 653-61.
83. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009; 9: 665-74.